Biotest Aktiengesellschaft (HAM:BIO3)
Germany · Delayed Price · Currency is EUR 32.20
0.00 (0.00%)
At close: Apr 29, 2026
Biotest Aktiengesellschaft Earnings Call Transcripts
Fiscal Year 2024
-
Sales grew 6% to €626 million in 2024, driven by new product launches and strong core sales, but EBIT fell due to lower technology transfer revenue. 2025 is expected to see a revenue decline and negative EBIT as R&D costs rise and price pressures persist. Delisting is planned, with Grifols offering €43/ordinary and €30/preference share.